The Management Team of the Company has many years of experience in the field of drug discovery and clinical development. Our Scientific Board is composed of scientific experts from independent organizations such as universities and governmental research institutes.
Peter M. Windisch, CEO
Peter M. Windisch is the Chief Executive Officer (CEO) of Anaxomics. Mr. Windisch has a remarkable
30-year career of leadership within the CRO industry. Before joining Anaxomics, Mr. Windisch served
as the Chief Technology Officer at Excelya in France, and prior to that, he was the Vice President
Operations and General Partner at PRA, and Vice President Operations Western Europe at RPS (now
From September 1st, 2023, with Mr. Windisch leading our charge, Anaxomics is poised for growth, innovation, and continued success in the realm of drug discovery and in silico clinical trials.
Jose Manuel Mas, PhD, Founder and CSO
José Manuel Mas is the Founder and Chief Scientific Officer (CSO) of Anaxomics Biotech. Prior to this, he served as the EU Head of Collaborative Research Department at RPS Inc. from 2008 to 2012 and was the co-founder and Chief Technology Officer at Infociencia for 10 years from 1998 to 2008. José Manuel holds a degree in Biochemistry, a Master’s degree in Biotechnology and a PhD in Biocomputing by the Autonomous University of Barcelona, specializing in protein structure modelling, drug design and systems biology. He has extensive experience in the development of biocomputational tools and machine learning techniques.
Laura Artigas, MSc, COO
Laura Artigas is the COO at Anaxomics Biotech SL. She has a degree in Biotechnology and Biochemistry, MSc in Molecular Biotechnology. Previously she belonged to the research team of the Molecular Biology and Biochemistry Research Center for Nanomedicine of Hospital de la Vall d'Hebrón de Barcelona, Spain. Laura has broad experience in project management and in transferring biological knowledge to the computational domain (building computable descriptions of available molecular, biochemical, and physiological data).
Mireia Coma, PhD, Medical Director & Business Development Director
Mireia Coma is the Medical Director and Business Development Director of Anaxomics Biotech SL. She has a degree in Biochemistry, MSc in Experimental Biochemistry and PhD in Health and Life Science. Previously she was a research fellow at the Memory Unit at Santa Creu i Sant Pau Hospital, Barcelona, Spain and at MassGeneral Institute for Neurodegenerative Disease, Harvard Medical School, Boston, MA, USA. Throughout her career, she has worked from basic research to applied solutions for the drug discovery and development process. Mireia has extensive experience in designing and coordinating of Artificial Intelligence-driven studies to optimize and add value to pharmaceutical companies’ products.
Judith Farrés, PhD, Head of Collaborative Research
Judith Farrés is the Head of Collaborative Research at Anaxomics. She holds a degree in Biochemistry, a Master’s degree and a PhD in Biotechnology. She was previously research fellow at the Institute of Biotechnology ETH Zürich for 6 years and EU project manager assistant at UAB Barcelona for 2 years. Since 2009 she is leading the research and innovation in Anaxomics, the application of biocomputational tools based on systems biology to different pathological backgrounds.
Cristina Segu, MSc, Chief Compliance Officer
Cristina Segú is the Chief Compliance Officer (CCO) at Anaxomics Biotech SL. She has a degree in Biotechnology, and is MSc in Biological Anthropology. She performed her master thesis with the research team of the Pathological Anatomy Service of Germans Trias Hospital in Badalona, Spain. Cristina has broad experience in project management and in transferring biological knowledge to the computational domain (building computable descriptions of available molecular, biochemical, and physiological data). She is in charge of the upkeep, update and design of procedures to comply with Anaxomics policies and quality standards, both from a scientific and management point of view.
Joan Bigorra, MD, PhD
Currently Director of Innovation at Barcelona Institute for Global Health and Senior Advisor of Innovation at University of Barcelona Clínic Hospital. Joan Bigorra was formerly appointed as Scientific Director of the Master in Leadership and Management of Science and Innovation (UB, UAB,UPF Interuniversity program, Barcelona) and Managing Director of Fundació Clínic per a la Recerca Biomèdica. He filled several key positions in Business and R&D management in leading Pharma Industries, such as Managing Director of Novartis Pharma Spain, Head of Medicine and R&D at Bayer HealthCare and later at Boehringer Ingelheim. Joan holds several degrees in General Management and Finance (IESE and Harvard Business School) and is the author of a considerable number of publications and book chapters on R&D management and health outcomes research.
F. Xavier Gomis-Rüth, PhD
Professor F. Xavier Gomis-Rüth studied organic chemistry at the Chemical Institute of Sarrià (IQS, Barcelona, Spain) where he obtained his BSc and MSc (1989). He got his PhD in protein crystallography in 1992 under the supervision of the Nobel laureate Robert Huber (1988) at the Max-Planck-Institute of Biochemistry (MPIB, Martinsried, Germany). After postdoctoral stays at the Autonomous University of Barcelona (Catalonia), the MPIB, and the Molecular Biology Institute of Barcelona (IBMB) of the Higher Scientific Research Council (CSIC), he was appointed tenured Assistant Professor position at CSIC in 2000. Since 2008, he is Full Professor at CSIC and Head of the Proteolysis Lab at IBMB, which is located in the premises of Barcelona Science Park (PCB). The Proteolysis Lab focuses on the study of proteins by molecular and structural biology to ascertain structure-function relationships following an experimental approach.
Xavier Daura, PhD
Xavier Daura is Research Professor at the Catalan Institution for Research and Advanced Studies (ICREA) and Principal Investigator of the group for Computational Biology in the Institute of Biotechnology and Biomedicine (IBB) of Universitat Autònoma de Barcelona (UAB). He is BSc in Biological Sciences MSc in Biotechnology and PhD in Biological Sciences by UAB, and was a postdoctoral researcher for six years at the Swiss Federal Institute of Technology (ETH) in Zurich. The main focus of his current research is in the development of new strategies to fight bacterial infections, combining a range of computational and experimental techniques for the identification of candidate bacterial components for synthetic vaccines and antimicrobial targets with new modes of action.
Baldomero Oliva, PhD
Biomedical Informatics, Baldo Oliva was formely technical Director of Bioinformatic services in Universitat Autònoma de Barcelona (UAB), Vice-dean of the School of Life and Health Sciences and Secretary of the Department of Experimental and Health sciences at UPF. He holds a PhD from UAB , with research stays in Uppsala University, Imperial Cancer Research Fund (London), Rockefeller University (New York), EMBL(Heidelberg) and Leloir Institute (Buenos Aires). He is author of a large number of peer reviewed articles and book chapters, member of Editorial Boards of BMC Bioinformatics and director of several doctoral theses. Principal Investigator of several projects granted by the spanish government, project co-leader in EraSysBio+ grant (SHIPREC), Baldo is co-participant of 2 patents (in EU and USA).